Nevertheless, resistance to immune checkpoint inhibitor therapies is common, with approximately 55% of melanoma patients showing innate resistance to single agent PD1 inhibitor (with ~40% innate resistance to CTLA4+PD1 inhibitor combination), and almost 25% of responding patients acquiring resistance to PD1 inhibitor within 2 years of treatment5. This evidence concerns the gene CTLA4 and melanoma.